222 related articles for article (PubMed ID: 18703645)
21. In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes.
Quintieri L; Fantin M; Palatini P; De Martin S; Rosato A; Caruso M; Geroni C; Floreani M
Biochem Pharmacol; 2008 Sep; 76(6):784-95. PubMed ID: 18671948
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
[TBL] [Abstract][Full Text] [Related]
23. Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. administration to rats and dogs.
Huskey SE; Luffer-Atlas D; Dean BJ; McGowan EM; Feeney WP; Chiu SH
Drug Metab Dispos; 1999 Nov; 27(11):1367-73. PubMed ID: 10534323
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
[TBL] [Abstract][Full Text] [Related]
25. Dose-independent pharmacokinetics of a new peroxisome proliferator-activated receptor-γ agonist, KR-62980, in Sprague-Dawley rats and ICR mice.
Park JS; Kim MS; Song JS; Choi SH; Lee BH; Woo J; Ahn JH; Bae MA; Ahn SH
Arch Pharm Res; 2011 Dec; 34(12):2051-8. PubMed ID: 22210030
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver.
Erion MD; Reddy KR; Boyer SH; Matelich MC; Gomez-Galeno J; Lemus RH; Ugarkar BG; Colby TJ; Schanzer J; Van Poelje PD
J Am Chem Soc; 2004 Apr; 126(16):5154-63. PubMed ID: 15099098
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human.
Attkins N; Betts A; Hepworth D; Heatherington AC
Xenobiotica; 2010 Nov; 40(11):730-42. PubMed ID: 20836725
[TBL] [Abstract][Full Text] [Related]
29. Disposition of abouthiouzine: a novel antihyperthyroid drug.
Alkharfy KM; Khan RM; Al-Hadiya BM; Abou-Auda HS; Abou-Shaaban RR
Biopharm Drug Dispos; 2007 Apr; 28(3):105-11. PubMed ID: 17230598
[TBL] [Abstract][Full Text] [Related]
30. Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
Dang Q; Liu Y; Cashion DK; Kasibhatla SR; Jiang T; Taplin F; Jacintho JD; Li H; Sun Z; Fan Y; DaRe J; Tian F; Li W; Gibson T; Lemus R; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2011 Jan; 54(1):153-65. PubMed ID: 21126019
[TBL] [Abstract][Full Text] [Related]
31. Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats.
Perkins EJ; Cramer JW; Farid NA; Gadberry MG; Jackson DA; Mattiuz EL; O'Bannon DD; Weiss HJ; Wheeler WJ; Wood PG; Cassidy KC
Drug Metab Dispos; 2003 Nov; 31(11):1382-90. PubMed ID: 14570771
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
Jung D; Lin L; Jiao H; Cai X; Duan JX; Matteucci M
Cancer Chemother Pharmacol; 2012 Mar; 69(3):643-54. PubMed ID: 21964906
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism.
Anand BS; Katragadda S; Mitra AK
J Pharmacol Exp Ther; 2004 Nov; 311(2):659-67. PubMed ID: 15226381
[TBL] [Abstract][Full Text] [Related]
34. Oxidative in vitro metabolism of liquiritigenin, a bioactive compound isolated from the Chinese herbal selective estrogen beta-receptor agonist MF101.
Kupfer R; Swanson L; Chow S; Staub RE; Zhang YL; Cohen I; Christians U
Drug Metab Dispos; 2008 Nov; 36(11):2261-9. PubMed ID: 18669586
[TBL] [Abstract][Full Text] [Related]
35. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.
Ward KW; Azzarano LM; Bondinell WE; Cousins RD; Huffman WF; Jakas DR; Keenan RM; Ku TW; Lundberg D; Miller WH; Mumaw JA; Newlander KA; Pirhalla JL; Roethke TJ; Salyers KL; Souder PR; Stelman GJ; Smith BR
Drug Metab Dispos; 1999 Nov; 27(11):1232-41. PubMed ID: 10534306
[TBL] [Abstract][Full Text] [Related]
36. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
[TBL] [Abstract][Full Text] [Related]
37. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: Pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein.
Fujisaki J; Tokunaga Y; Sawamoto T; Takahashi T; Kimura S; Shimojo F; Hata T
J Drug Target; 1996; 4(2):117-23. PubMed ID: 8894972
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
Zhou L; Dockens RC; Liu-Kreyche P; Grossman SJ; Iyer RA
Drug Metab Dispos; 2012 Jun; 40(6):1093-103. PubMed ID: 22381334
[TBL] [Abstract][Full Text] [Related]
39. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey.
Ward KW; Azzarano LM
J Pharmacol Exp Ther; 2004 Aug; 310(2):703-9. PubMed ID: 15056727
[TBL] [Abstract][Full Text] [Related]
40. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
Yu RZ; Kim TW; Hong A; Watanabe TA; Gaus HJ; Geary RS
Drug Metab Dispos; 2007 Mar; 35(3):460-8. PubMed ID: 17172312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
